PUBLISHER: Acute Market Reports | PRODUCT CODE: 1260065
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1260065
Real World Evidence Solution Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
The global market for real-world evidence solutions is expected to grow at a CAGR of 15% during the forecast period of 2023 to 2031. This market's expansion is primarily driven by the primary factors driving the growth of this market are the expansion of clinical trials and the change from volume-based to value-based treatment. Utilizing RWE and RWD can improve protocol design, hence reducing the number of costly protocol changes, and enabling the creation of synthetic control arms to speed up trial execution and save expenses. Similarly, RWE can expedite label expansion and reduce the overall cost of filing-required documentation. Due to these benefits, the adoption of RWE systems in drug and medical device research and development is increasing. Support from regulatory bodies for the use of Real-World Evidence (RWE) solutions and a rise in R&D expenditures are expected to stimulate market growth. In addition, the shift from volume-based to value-based care is anticipated to contribute to the rise. As a result of the COVID-19 pandemic, numerous market participants began to experience widespread business disruptions, which hindered routine corporate operations.
Increased Investment in Research and Development
The majority of pharmaceutical, biopharmaceutical, and medical device businesses continue to make substantial investments in the development of novel medications and technologies. Particularly, the pharmaceutical business is heavily invested in R&D. To meet the demands of both drug discovery and development, pharmaceutical and biopharmaceutical businesses are opting for fully integrated or functional outsourcing services, from the early development phase to the late-stage development phase, due to increased R&D expenditures. The pharmaceutical industry spends the highest proportion of its income on research and development compared to all other industries. This increase in R&D spending, spurred by the requirement for multiple preclinical and clinical services during the drug development process, is anticipated to fuel the expansion of the RWE market.
Medical Practitioners and Academics' Reluctance to Rely on Real-World Evidence Solutions
Despite the widespread use of RWE across applications, certain stakeholders continue to be hesitant to rely on real-world evidence. For instance, although payers have begun using RWE, they prefer to base drug coverage decisions on randomized clinical trials (RCTs) rather than external observational data. The primary reason for this preference is the provision of numerous standards and methodologies for examining clinical experience evidence derived from actual patient care. In addition, payers utilize a wide range of procedures and evidence when determining pharmaceutical coverage. During the pharmaceutical technology assessment (PTA) procedure, these differences can impact reimbursement, patient access, and potential healthcare outcomes. Therefore, stakeholders are hesitant to use evidence without a standardized data-gathering strategy.
Increased Emphasis on RWE's End-To-End Services
As players in the healthcare business seek innovative solutions to address the unsustainable cost burden and relatively low return on investment, the healthcare ecosystem is transforming, and there is a growing focus on healthcare costs. To demonstrate value, businesses require robust capabilities in evidence lifecycle management. Consequently, an opportunity for an end-to-end approach to leverage the data, evidence, and knowledge assets of a life sciences organization has been created, which is aiding in the dismantling of conventional silos and enabling insight-driven decision-making from the product R&D phase to its commercialization. This entails creating an effective governance plan and using technologies like cloud and self-service analytics, as well as acquiring the capacity to integrate data sets and comprehend the relevant resources for the required analytics (and tactical issues around data access and quality).
Absence Of Globally Acknowledged Methodology Standards and Data Processing Infrastructure
In this sector, the lack of globally agreed standards or principles that may be used in the design, analysis, and reporting of RWE has become a serious obstacle. This lack of unanimity has resulted in RWE not being of sufficient quality to be included in the body of evidence used to compare the efficacy of various treatment approaches. This has decreased the potential value of the produced information, hence decreasing the incentive to produce it. This further diminishes the likelihood that significant stakeholders will use RWE solutions.
In 2022, The Services Category Dominated the RWE Solutions Market
The rising requirement to translate data into actionable evidence and the availability of a vast quantity of healthcare data are the primary reasons driving the expansion of this market sector. Clients can save time and money by relying on vendors to tailor their services to their specific needs, as opposed to acquiring data sets and analyzing them to generate valuable information. Consequently, the demand for RWE services is greater than that for RWE data sets. Experts in RWE communicate and work with the subject matter expert of pharmaceutical and medical device firms to provide services to establish intelligent RWE plans (consulting services) and employ analytical capabilities to provide significant statistical insights.
In 2022, The Drug Development and Approvals Segment Led the RWE Solutions Market
Due to the increasing number of clinical studies in oncology and cardiovascular medicines, the drug development and approvals market segment is the most significant. In addition, post-pandemic treatment advancements for the COVID-19 infection had a substantial increase. This division is further subdivided into oncology, cardiovascular disease, neurology, immunology, and other therapeutic fields. Due to the rising incidence of cancer and the growing number of clinical trials and research focusing on cancer treatment and prevention, the oncology segment leads the market.
Pharmaceutical And Medical Device Firms Are Anticipated to be The Fastest Growing End Users Segment
The rapid rise of pharmaceutical and medical device firms is attributable to the growing significance of RWE studies in medication approvals, the prevention of costly drug recalls, and the evaluation of therapeutic performance in real-world contexts. In addition, the pharmaceutical industry's use of RWE continues to rise due to its application in addressing regulatory compliance requirements and payer obligations connected to HEOR. Pharmaceutical businesses demand information detailing both the approved and medically acknowledged alternative uses for previously approved medications. For novel medications to effectively progress through clinical phases, RWE data is required. Therefore, the successful phase transition is contingent upon robust real-world results.
North America remains the Global Leader, and APAC is the Growth Leader
North America held the greatest share of the RWE solutions market, while Asia-Pacific is anticipated to maintain the highest growth rate over the forecast period. Supporting the growth of the RWE solutions market in the Asia Pacific region are factors such as the rising number of clinical trials, increasing government initiatives for the adoption of RWE studies, the rising incidence of chronic diseases, the rising demand for better healthcare services, and the rising geriatric population. Moreover, nations such as Japan and China in the region have a well-established clinical trial infrastructure, a strong medical workforce, solid healthcare capabilities, and high-quality requirements, all of which contribute to the growth of the market in the Asia Pacific.
Market Competition to Intensify During the Forecast Period
The worldwide market is highly fragmented and competitive. Through subsidiaries and partnerships, market participants implement strategic initiatives such as product development and launch, distribution network expansion, and global footprint expansion. In addition to portfolio diversification and mergers & acquisitions, key players engage in portfolio diversification and mergers & acquisitions. For example, in August 2021, Syneos Health teamed with Aetion to develop a solution based on real-world evidence and to give analytically-driven data and regulatory-grade data. Similarly, Thermo Fisher Scientific announced in April 2021 that it will purchase PPD, Inc. for USD 47.50 per share. The key companies that are active in the market include IQVIA, IBM, ICON plc., PAREXEL International Corporation, PPD, LLC, Optum, Inc., Cognizant Technology Solutions Corporation, Oracle Corporation, SAS Institute Inc., Syneos Health, Inc., Anthem, Inc., Clinigen Group plc., Medpace Holdings Inc., Flatiron Health and Other notable players.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Real World Evidence Solution market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report
Micro and macro environment factors that are currently influencing the Real World Evidence Solution market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Component
Services
Data Sets
Disparate Data Sets
Clinical Settings Data
Claims Data
Pharmacy Data
Patient-Powered Data
Registry-Based Data Sets
Integrated Data Sets
Application
Drug Development And Approvals
Oncology
Neurology
Immunology
Cardiovascular Disease
Other Therapeutic Areas
Medical Device Development And Approvals
Post-Market Surveillance
Market Access Reimbursement/Coverage Decision Making
Clinical And Regulatory Decision-Making
End User
Pharmaceutical & Medical Device Companies
Healthcare Providers
Healthcare Payers
Other End Users
Region Segment (2021-2031; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Real World Evidence Solution market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2031.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Real World Evidence Solution market?
Which is the largest regional market for Real World Evidence Solution market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Real World Evidence Solution market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Real World Evidence Solution market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Real World Evidence Solution Market
- 2.2. Global Real World Evidence Solution Market, By Component, 2022 (US$ Million)
- 2.3. Global Real World Evidence Solution Market, By Application, 2022 (US$ Million)
- 2.4. Global Real World Evidence Solution Market, By End User, 2022 (US$ Million)
- 2.5. Global Real World Evidence Solution Market, By Geography, 2022 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2022
3. Real World Evidence Solution Market: Competitive Analysis
- 3.1. Market Positioning of Key Real World Evidence Solution Market Vendors
- 3.2. Strategies Adopted by Real World Evidence Solution Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2022 Versus 2031
4. Real World Evidence Solution Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Real World Evidence Solution Market Value, 2021 - 2031, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2022 Versus 2031
- 5.3. Market Segmentation
- 5.3.1. Services
- 5.3.2. Data Sets
- 5.3.2.1. Disparate Data Sets
- 5.3.2.1.1. Clinical Settings Data
- 5.3.2.1.2. Claims Data
- 5.3.2.1.3. Pharmacy Data
- 5.3.2.1.4. Patient-Powered Data
- 5.3.2.1.5. Registry-Based Data Sets
- 5.3.2.2. Integrated Data Sets
- 5.3.2.1. Disparate Data Sets
6. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2022 Versus 2031
- 6.3. Market Segmentation
- 6.3.1. Drug Development And Approvals
- 6.3.1.1. Oncology
- 6.3.1.2. Neurology
- 6.3.1.3. Immunology
- 6.3.1.4. Cardiovascular Disease
- 6.3.1.5. Other Therapeutic Areas
- 6.3.1.6. Medical Device Development And Approvals
- 6.3.2. Post-Market Surveillance
- 6.3.3. Market Access Reimbursement/Coverage Decision Making
- 6.3.4. Clinical And Regulatory Decision-Making
- 6.3.1. Drug Development And Approvals
7. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2022 Versus 2031
- 7.3. Market Segmentation
- 7.3.1. Pharmaceutical & Medical Device Companies
- 7.3.2. Healthcare Providers
- 7.3.3. Healthcare Payers
- 7.3.4. Other End Users
8. North America Real World Evidence Solution Market, 2021-2031, USD (Million)
- 8.1. Market Overview
- 8.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 8.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 8.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 8.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 8.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 8.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 8.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 8.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 8.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 8.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 8.5.1.1. U.S.
- 8.5.1.North America
9. UK and European Union Real World Evidence Solution Market, 2021-2031, USD (Million)
- 9.1. Market Overview
- 9.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 9.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 9.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 9.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 9.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 9.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 9.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 9.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 9.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 9.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 9.5.1.4.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 9.5.1.4.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 9.5.1.5.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 9.5.1.5.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 9.5.1.6.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 9.5.1.6.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 9.5.1.1. UK
- 9.5.1.UK and European Union
10. Asia Pacific Real World Evidence Solution Market, 2021-2031, USD (Million)
- 10.1. Market Overview
- 10.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 10.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 10.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 10.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 10.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 10.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 10.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 10.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 10.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 10.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 10.5.1.4.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 10.5.1.4.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 10.5.1.5.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 10.5.1.5.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 10.5.1.6.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 10.5.1.6.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 10.5.1.1. China
- 10.5.1.Asia Pacific
11. Latin America Real World Evidence Solution Market, 2021-2031, USD (Million)
- 11.1. Market Overview
- 11.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 11.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 11.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 11.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 11.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 11.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 11.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 11.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 11.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 11.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 11.5.1.1. Brazil
- 11.5.1.Latin America
12. Middle East and Africa Real World Evidence Solution Market, 2021-2031, USD (Million)
- 12.1. Market Overview
- 12.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 12.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 12.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 12.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 12.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 12.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 12.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 12.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
- 12.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
- 12.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
- 12.5.1.1. GCC
- 12.5.1.Middle East and Africa
13. Company Profile
- 13.1. IQVIA (US)
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. IBM (US)
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. ICON plc. (Ireland)
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. PAREXEL International Corporation (US)
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. PPD, LLC (US)
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. Optum, Inc. (US)
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. Cognizant Technology Solutions Corporation (US)
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. Oracle Corporation (US)
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. SAS Institute Inc. (US)
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. Syneos Health, Inc. (US)
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. Anthem, Inc. (US)
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
- 13.12. Clinigen Group plc. (UK)
- 13.12.1. Company Overview
- 13.12.2. Financial Performance
- 13.12.3. Product Portfolio
- 13.12.4. Strategic Initiatives
- 13.13. Medpace Holdings Inc. (US)
- 13.13.1. Company Overview
- 13.13.2. Financial Performance
- 13.13.3. Product Portfolio
- 13.13.4. Strategic Initiatives
- 13.14. Flatiron Health (US)
- 13.14.1. Company Overview
- 13.14.2. Financial Performance
- 13.14.3. Product Portfolio
- 13.14.4. Strategic Initiatives
- 13.15. Others
- 13.15.1. Company Overview
- 13.15.2. Financial Performance
- 13.15.3. Product Portfolio
- 13.15.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 2 Global Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 3 Global Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 4 Global Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 5 Global Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 6 Global Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 7 North America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 8 North America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 9 North America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 10 North America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 11 North America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 12 North America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 13 U.S. Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 14 U.S. Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 15 U.S. Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 16 U.S. Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 17 U.S. Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 18 U.S. Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 19 Canada Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 20 Canada Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 21 Canada Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 22 Canada Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 23 Canada Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 24 Canada Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 25 Rest of North America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 26 Rest of North America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 27 Rest of North America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 28 Rest of North America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 29 Rest of North America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 30 Rest of North America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 31 UK and European Union Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 32 UK and European Union Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 33 UK and European Union Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 34 UK and European Union Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 35 UK and European Union Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 36 UK and European Union Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 37 UK Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 38 UK Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 39 UK Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 40 UK Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 41 UK Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 42 UK Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 43 Germany Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 44 Germany Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 45 Germany Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 46 Germany Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 47 Germany Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 48 Germany Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 49 Spain Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 50 Spain Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 51 Spain Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 52 Spain Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 53 Spain Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 54 Spain Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 55 Italy Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 56 Italy Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 57 Italy Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 58 Italy Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 59 Italy Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 60 Italy Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 61 France Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 62 France Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 63 France Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 64 France Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 65 France Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 66 France Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 67 Rest of Europe Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 68 Rest of Europe Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 69 Rest of Europe Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 70 Rest of Europe Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 71 Rest of Europe Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 72 Rest of Europe Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 73 Asia Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 74 Asia Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 75 Asia Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 76 Asia Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 77 Asia Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 78 Asia Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 79 China Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 80 China Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 81 China Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 82 China Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 83 China Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 84 China Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 85 Japan Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 86 Japan Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 87 Japan Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 88 Japan Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 89 Japan Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 90 Japan Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 91 India Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 92 India Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 93 India Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 94 India Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 95 India Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 96 India Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 97 Australia Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 98 Australia Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 99 Australia Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 100 Australia Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 101 Australia Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 102 Australia Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 103 South Korea Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 104 South Korea Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 105 South Korea Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 106 South Korea Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 107 South Korea Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 108 South Korea Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 109 Latin America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 110 Latin America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 111 Latin America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 112 Latin America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 113 Latin America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 114 Latin America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 115 Brazil Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 116 Brazil Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 117 Brazil Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 118 Brazil Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 119 Brazil Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 120 Brazil Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 121 Mexico Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 122 Mexico Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 123 Mexico Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 124 Mexico Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 125 Mexico Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 126 Mexico Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 127 Rest of Latin America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 128 Rest of Latin America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 129 Rest of Latin America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 130 Rest of Latin America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 131 Rest of Latin America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 132 Rest of Latin America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 133 Middle East and Africa Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 134 Middle East and Africa Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 135 Middle East and Africa Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 136 Middle East and Africa Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 137 Middle East and Africa Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 138 Middle East and Africa Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 139 GCC Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 140 GCC Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 141 GCC Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 142 GCC Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 143 GCC Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 144 GCC Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 145 Africa Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 146 Africa Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 147 Africa Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 148 Africa Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 149 Africa Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 150 Africa Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
- TABLE 151 Rest of Middle East and Africa Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
- TABLE 152 Rest of Middle East and Africa Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
- TABLE 153 Rest of Middle East and Africa Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
- TABLE 154 Rest of Middle East and Africa Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
- TABLE 155 Rest of Middle East and Africa Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
- TABLE 156 Rest of Middle East and Africa Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
List of Figures
- FIG. 1 Global Real World Evidence Solution Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Real World Evidence Solution Market: Quality Assurance
- FIG. 5 Global Real World Evidence Solution Market, By Component, 2022
- FIG. 6 Global Real World Evidence Solution Market, By Application, 2022
- FIG. 7 Global Real World Evidence Solution Market, By End User, 2022
- FIG. 8 Global Real World Evidence Solution Market, By Geography, 2022
- FIG. 9 Market Geographical Opportunity Matrix - Global Real World Evidence Solution Market, 2022
- FIG. 10 Market Positioning of Key Real World Evidence Solution Market Players, 2022
- FIG. 11 Global Real World Evidence Solution Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
- FIG. 12 Global Real World Evidence Solution Market, By Component, 2022 Vs 2031, %
- FIG. 13 Global Real World Evidence Solution Market, By Application, 2022 Vs 2031, %
- FIG. 14 Global Real World Evidence Solution Market, By End User, 2022 Vs 2031, %
- FIG. 15 U.S. Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 16 Canada Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 17 Rest of North America Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 18 UK Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 19 Germany Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 20 Spain Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 21 Italy Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 22 France Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 23 Rest of Europe Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 24 China Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 25 Japan Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 26 India Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 27 Australia Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 28 South Korea Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 29 Rest of Asia Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 30 Brazil Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 31 Mexico Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 32 Rest of Latin America Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 33 GCC Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 34 Africa Real World Evidence Solution Market (US$ Million), 2021 - 2031
- FIG. 35 Rest of Middle East and Africa Real World Evidence Solution Market (US$ Million), 2021 - 2031
